The present invention relates to budesonide, or a salt thereof, or mixtures thereof for ophthalmic use in a method for the curative treatment of an eye disorder or ailment or disease in a subject in need. Further, the present invention relates to a composition comprising a mixture comprising or, alternatively, consisting of: (i) a budesonide, or a salt thereof, or mixtures thereof; (ii) at least one suspending/thickening agent, and optionally one or more physiologically and/or pharmacologically acceptable excipients; said composition being for use in a method for the curative treatment of an inflammation of the and ocular adnexa or inflammation of the eyeball in a subject in need.

Microparticulate drug compositions comprising nanocrystals of poorly soluble drugs combined with a carrier are disclosed. Also disclosed are pharmaceutical compositions that include the microparticulate drug compositions. Further disclosed are methods of preparing and using the microparticulate drug compositions/pharmaceutical compositions.

Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.

The present technology relates generally to dry powder formulations comprising leucine and trileucine in specific ratios that are suitable for pulmonary delivery. Also provided are methods of preparing the dry powder formulations, and methods of administration and treatment using the dry powder formulations.

Provided herein are rehydratable powdered formulations of nanocarriers that can be used to encompass hydrophobic or hydrophilic cargo. The formulations can be used for medicinal, agricultural, and research applications. Methods of making the formulations are also provided.

The present invention relates to a pharmaceutical granulate composition comprising Palbociclib free base, having improved bioavailability.

The disclosed invention relates to a low-dose celecoxib oral formulation, and a preparation method therefor, which is characterized in that the strength of the formulation is 60-90% of the original strength of the commercial celecoxib product, and the celecoxib formulation with such reduced strength is bioequivalent to the commercial celecoxib product. The celecoxib formulation can be used for the treatment of mild to moderate pain and mild to moderate chronic pain.

A solid pharmaceutical composition comprising a quinazoline derivative or a medicinal salt thereof, and a preparation method therefor. Specifically, provided is a solid pharmaceutical composition comprising N.sup.6-(1-acryloylpiperidin-4-yl)-N.sup.4-(3-chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine or a medicinal salt thereof, and a preparation method therefor and use thereof.

##STR00001##

This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.

The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such as Burkholderia pseudomallei and Francisella tularensis, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).